EUCTR2014-000445-79-DE进行中（未招募）1 期
A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in subjects with Merkel cellcarcinoma - JAVELIN Merkel 200
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Merck KGaA
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed written informed consent
- •Age 18 years and above
- •Histologically proven MCC as defined in the protocol
- •For Part A - Progressive disease after receiving 1 line of chemotherapy
- •for metastatic MCC
- •For Part B – Subjects must not have received any prior systemic
- •treatment for metastatic MCC. Prior chemotherapy treatment in the
- •adjuvant setting (no clinically detectable disease; no metastatic disease)
- •is allowable if the end of treatment occurred at least 6 months prior to
- •study start)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0
- •Estimated life expectancy of more than 12 weeks
- •Disease must be measurable with at least 1 uni-dimensional
- •measurable lesion by RECIST Version 1.1 (including skin lesions)
- •Adequate haematological and hepatic function.
- •Adequate renal function as per protocol definition
- •Fresh Biopsy or Archival Tumor Tissue (as per protocol definition for
- •Part A and Part B)
- •Highly effective contraception for both male and female subjects as per
- •protocol definition if the risk of conception exists.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 51
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 149
排除标准
- •1.Participation in another interventional clinical trial within the past 30 days (participation in observational studies is permitted)
- •2. Concurrent treatment with a nonpermitted drug
- •3. Prior therapy with any antibody/drug targeting T-cell coregulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anticytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody; for Part B, the Investigator must consult with the Medical Monitor and consider other co regulatory targets such as 4-1BB
- •4. Concurrent anticancer treatment (for example, cytoreductive therapy, radiotherapy [with the exception of palliative bone-directed radiotherapy, or radiotherapy administered on non-target superficial lesions], immune therapy, or cytokine therapy except for erythropoietin). Radiotherapy administered to superficial lesions is not allowed if such lesions are considered target lesions in the efficacy evaluation or may influence the efficacy evaluation of the investigational agent
- •5. Major surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the subject has not fully recovered from the surgery within 4 weeks
- •6. Concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of trial treatment. Short-term administration of systemic steroids (that is, for allergic reactions or the management of irAEs) is allowed while on study. Note:
- •Subjects receiving bisphosphonate or denosumab are eligible. Also,
- •subjects requiring hormone replacement with corticosteroids for adrenal
- •insufficiency are eligible if the steroids are administered only for the
- •purpose of hormonal replacement and at doses = 10 mg or equivalent
- •prednisone per day.
- •7. Subjects with active central nervous system (CNS) metastases are excluded. Subjects with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 2 months, and do not require continued steroid therapy
- •8. Previous malignant disease (other than MCC) within the last 5 years with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ
- •9. Prior organ transplantation, including allogeneic stem-cell transplantation
- •10. For Part A, Known history of testing positive for HIV or known acquired immunodeficiency syndrome (AIDS) or any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection. For Part B, known history of testing positive for HIV or known AIDS in consultation with the Medical Monitor or HBV or HCV
- •infection at screening (positive HBV surface antigen or HCV RNA if anti-
- •HCV antibody screening test positive)
- •11. Active or history of any autoimmune disease (except for subjects with vitiligo) or immunodeficiencies that required treatment with systemic immunosuppressive drugs
- •12. Known severe hypersensitivity reactions to monoclonal antibodies (Grade = 3 NCI-CTCAE v 4.0), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partly controlled asthma)
- •13. Persisting toxicity related to prior therapy Grade > 1 NCI-CTCAE v 4.0; however, sensory neuropathy Grade = 2 is acceptable
- •14. Pregnancy or lactation
- •15. Known alcohol or drug abuse
- •16. Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to
研究者
相似试验
进行中（未招募）
不适用
Avelumab (MSB0010718C) in Subjects With Merkel Cell CarcinomaMerkel Cell CarcinomaEUCTR2014-000445-79-ATMerck KGaA84
进行中（未招募）
不适用
MSB0010718C in Subjects With Skin CancerMerkel Cell CarcinomaMedDRA version: 17.0Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000004864EUCTR2014-000445-79-ITMerck KGaA84
进行中（未招募）
1 期
MSB0010718C in Subjects With Skin CancerMedDRA version: 17.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000004864Merkel Cell CarcinomaEUCTR2014-000445-79-ESMerck KGaA84
进行中（未招募）
1 期
Cabozantinib in combination with Avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3)Advanced neuroendocrine neoplasias G3 (NEN G3) (excluding SCLC and Merkel cell carcinomas)MedDRA version: 20.0Level: PTClassification code: 10057270Term: Neuroendocrine carcinoma Class: 100000004864CTIS2024-513518-37-00niversitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR30
进行中（未招募）
1 期
A study to investigate the clinical activity and safety of avelumab in patients with neuroendocrine carcinomasadvanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010)EUCTR2016-004373-40-DEniversity Medical Center of the Johannes Gutenberg-University Mainz60